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ABSTRACT	  
 
Recombinant activated human Factor VII (rFVIIa) is an established hemostatic agent in 
hemophilia but its mechanism of action remains unclear. Although tissue factor (TF) is its 
natural receptor, rFVIIa also interacts with the endothelial protein C receptor (EPCR) 
through its γ-carboxyglutamic acid (Gla) domain with unknown hemostatic consequences 
in vivo. Here, we study whether EPCR facilitates rFVIIa hemostasis in hemophilia using 
a mouse model system. Murine activated FVII (mFVIIa) is functionally homologous to 
rFVIIa, but binds poorly to murine EPCR (mEPCR). We modified mFVIIa to gain 
mEPCR binding using 3 amino acid changes in its Gla-domain. The resulting molecule 
mFVIIa-FMR specifically bound mEPCR in vitro and in vivo and was identical to 
mFVIIa with respect to TF affinity and procoagulant functions. Using two macrovascular 
injury models in hemophilic mice, administered mFVIIa-FMR exhibited superior 
hemostatic properties compared to mFVIIa. These effects were specific to the mFVIIa-
FMR and mEPCR interaction since antibody blocking of mEPCR abolished them. Since 
mFVIIa-FMR models both the TF-dependent as well as EPCR binding properties of 
rFVIIa, our data unmask a novel contribution of EPCR on the action of rFVIIa 
administration in hemophilia. This may prompt the rational design of improved and safer 
rFVIIa therapeutics. 
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SOMMARIO	  
 
Il Fattore VII attivato ricombinante (rFVIIa) è un agente emostatico utilizzato per il 
trattamento dei pazienti emofilici con inibitori, ma il suo meccanismo d’azione rimane ad 
oggi non completamente elucidato. Nonostante il Fattore Tissutale (TF) sia il suo 
cofattore naturale più importante, il rFVIIa interagisce attraverso il dominio γ-
carbossiglutammico (Gla) anche con il recettore endoteliale della Proteina C (PC) con 
conseguenze funzionali ancora sconosciute. 
In questo studio abbiamo caratterizzato l’effetto del legame ad EPCR sull’attività 
emostatica del FVIIa, utilizzando un modello murino di emofilia. Nel topo il FVIIa 
murino (mFVIIa), nonostante l’alta omologia funzionale e strutturale con l’omologo 
umano, non interagisce con EPCR. Per trasformare il mFVIIa in un ligando di mEPCR 
senza intaccare le sue proprietà coagulative  abbiamo generato una variante di mFVIIa 
(mFVIIa-FMR) modificando tramite mutagenesi 3 residui del dominio Gla. Questa 
variante è in grado di legare in modo specifico mEPCR e mantenere le stesse 
caratteristiche funzionali di mFVIIa in vitro. Per queste sue proprietà mFVIIa-FMR 
rappresenta la molecola ideale per caratterizzare in vivo l’effetto di EPCR sull’attività del 
FVIIa. In topi emofilici sottoposti a danno vascolare. mFVIIa-FMR ha dimostrato 
maggiori proprietà emostatiche rispetto al mFVIIa. Questo effetto procoagulante dipende 
dal legame specifico di mFVIIa-FMR con EPCR.  
Questo lavoro identifica per la prima volta EPCR come un nuovo modulatore dell’attività 
del FVIIa in vivo. La comprensione più dettagliata del meccanismo con cui EPCR 
aumenta l’attività coagulante del FVIIa potrà promuovere lo sviluppo di nuove molecole 
terapeutiche con maggiore attività emostatica per il trattamento dell’emofilia. 
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INTRODUCTION	  
 
The	  blood	  coagulation	  system	  
 
Coagulation involves a multitude of proteins and cellular partners that act in concert in 
response to a vascular injury to generate thrombin, which is responsible for the 
generation of the fibrin plug (Figure 1). However, while fibrin generation is required for 
the arrest of excessive bleeding, unregulated clotting may lead to vascular occlusion and 
result in myocardial infarction, stroke, pulmonary embolism, or venous thrombosis. Thus, 
the regulation of the delicate balance between the procoagulant and anticoagulant 
mechanisms is of fundamental for survival(Dahlback, 2005) 
The dynamics of the blood coagulation system are dominated by three membrane-bound 
procoagulant complexes which assemble at the site of vascular injury on platelets, the 
damaged endothelium and subvascular tissue (Figure 2)(Mann et al., 2003). The 
assembly and regulation of these complexes and their opposing anticoagulant systems 
dictate the coagulant response. 
 
Fig. 1 The blood coagulation response, image courtesy of Dr. Rodney M. Camire, The 
Children’s Hospital of Philadelphia 
 6 
The	  clotting	  cascade	  
 
The clotting cascade is shown in Figure 3. Initiation of coagulation begins by exposure of 
Tissue Factor (TF) to the bloodstream, through physical damage to the lining of the blood 
vessel or increased expression in endothelial and monocytes in response to certain 
inflammatory signals. About 1-2 % of Factor VII (FVII) circulates in its activated form 
(FVIIa) and binds rapidly to TF after exposure (Vadivel and Bajaj, 2012). The FVIIa-TF 
complex efficiently converts factor IX (FIX) and factor X (FX) to active enzymes FIXa 
and FXa, which together with factor VIIIa (FVIIIa) and factor Va (FVa), respectively, 
propagate the coagulation process.(Dahlback, 2005) 
With sufficient stimulus, the FXa produced activates some prothrombin. This initial 
thrombin activates the procofactors and platelets required for presentation of the intrinsic 
FXase (FVIIIa-FIXa) and prothrombinase (FVa-FXa) complexes that drive the 
subsequent propagation phase. During this phase the intrinsic FXase drives most of the 
FXa generated, and the reaction becomes TF independent. (Mann et al., 2003).  
When FXa combines with FVa on the activated platelet surface or other activated 
membranes (e.g. endothelium), the complex FXa/FVa (prothrombinase) efficiently 
converts prothrombin to thrombin, resulting in fibrin generation and, ultimately, clot 
formation. 
 
Fig. 2 The 3 vitamin K–dependent procoagulant complexes. The thicker arrow 
associated with intrinsic factor Xase generation of factor Xa reflects the improved 
catalytic efficiency of this complex. Adapted from (Mann et al., 2003) 
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The assembly of the prothrombinase complex is crucial since it is 300,000-fold more 
active than factor Xa alone in catalyzing prothrombin activation.(Mann, 2003)  
 
 
Fig 3. General overview of the clotting cascade. Green arrows indicate positive 
feedback reactions, in red inhibitory pathway. (Wikipedia Commons) 
 
It is critical that once a procoagulant response to vascular injury has been initiated that an 
appropriate anticoagulant response is concurrently mounted. As such, the components of 
the prothrombinase complex are targets of multiple regulatory mechanisms to arrest the 
production of thrombin. First, TF dependent activation of coagulation is regulated by 
tissue factor pathway inhibitor (TFPI), a FXa-dependent inhibitor of the FVIIa/TF 
complex (Shirk and Vlasuk, 2007). The mechanism of inhibition by TFPI involves its 
binding first to FXa through domain 2 and then to the TF/FVIIa complex through domain 
1(Rao and Mackman, 2010). FXa is also inhibited by serpins such as antithrombin (AT), 
α1-antitrypsin. The cofactor, FVa, is a target for degradation by activated protein C 
(aPC). aPC, a serine protease derived from its plasma precursor protein C (PC) in a 
thrombin dependent activation process (Bravo et al., 2012; McVey et al., 1998), plays a 
critical role in inactivating the non-enzymatic cofactor components of both the 
prothrombinase and the intrinsic FXase complexes, factors Va and VIIIa, respectively. 
Additional key components of the PC pathway include: thrombomodulin and endothelial 
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protein C receptor (EPCR) which regulate PC activation; protein S which acts as a 
cofactor for aPC; and protein C inhibitor, a suppressor of aPC formation (McVey et al., 
2001; Wildhagen et al., 2011).  
Coagulation	  Factor	  VII	  	  
 
Factor VII is a vitamin K-dependent glycoprotein that participates in the initiation of the 
extrinsic pathway of blood coagulation. It is expressed and synthesized in the liver where 
is secreted as single-chain zymogen composed of 406 amino acid residues (Mr 50,000 
kD). The factor VII gene (F7) consists in 9 exons and it is located on chromosome 13q34, 
2.8 kb upstream of the FX gene. F7 shares significant similarity with other genes coding 
for vitamin K-dependent proteins(Greenberg et al., 1995). It is believed that these 
proteins have been assembled by exon-shuffling events via intronic recombination 
(Patthy, 1985). Inherited FVII deficiency is an autosomal recessive disease with variable 
clinical symptoms (Mariani and Bernardi, 2009). FVII deficiency is not associated with 
complete absence of functional FVII, suggesting that a complete lack of FVII is 
incompatible with life (McVey et al., 1998). As described in clinical reports, homozygous 
carriers die shortly after birth due to severe hemorrhage (McVey et al., 2001). The same 
phenotype was observed in F7 knockout mice models (Rosen et al., 2005).  
The genetic similarity with other clotting factors is also reflected by high structural 
homology and domain organization at a protein level (Figure 4). FVII consist of a γ-
carboxyglutamic acid (Gla) domain which enables reversible binding to phospholipid 
membranes, a hydrophobic stack, which is involved in formation of the ternary complex, 
two epidermal growth factor-like domains (EGF 1-2), and a protease domain (Bajaj et al., 
2006). The Gla domain is a hallmark of all vitamin K-dependent coagulation proteins; 
FVII has 10 glutamic acid residues that undergo a characteristic post-translational 
carboxylation at the γ-carbon. Gla residues are necessary for calcium binding which 
induces a conformational change in the Gla domain required for phospholipid/receptor 
binding and therefore clotting activity (Larson et al., 1998). FVII Gla domain coordinates 
7 divalent cations: crystal structures obtained in presence of  2.5 mM Mg2+/5 mM Ca2+ 
indicate that metal positions 1, 4, and 7 are occupied by Mg2+ while the remaining 4 sites 
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coordinate Ca2+. Other post-translational modifications in FVII include N-glycosylations 
(Asn145, Asn322) and O-glycosylations (Ser52, Ser60). There are also two other calcium 
binding sites located in EGF1 and in the serine protease domain(Hansson and Stenflo, 
2005).  
 
 
 
Approximately 99% of FVII circulates as inactive zymogen. The initial event, cleavage 
of the peptide bond between Arg152/Ile153, converts the zymogen FVII into a two-chain 
serine protease linked by a disulfide bond that exists in equilibrium between a 
predominant zymogen-like form and an active FVIIa. In the zymogen-like conformation, 
the new N-terminus of Ile153 is solvent-exposed and accessible to modification, whereas 
in the active FVIIa, a salt bridge forms between the α-amino group of Ile 153 and the β-
carboxyl group of Asp343, stabilizing the insertion of Ile153 into the protein (Toso et al., 
Fig 4 Structure of FVIIa/sTF complexes. 
The FVIIa/sTF structure of Bajaj et al., at 
1.8 angstrom resolution (PDB id 2A2Q) in 
the presence of Ca2+ and Mg2+ is shown. 
FVIIa consists of Gla (red), EGF1 (green), 
EGF2 (blue) and protease (cyan) domains, 
and the sTF (magenta) contains two 
fibronection type III domains. The different 
metal ions Ca2+(orange), Mg2+(green), Zn2+ 
(light blue) and Na+ (purple), bound to 
different domains of FVIIa are shown as 
spheres. Adapted from (Vadivel	   and	   Bajaj,	  2012) 
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2003). TF binding facilitates the stabilizing insertion of the N-terminal tail of the protease 
domain of FVII into the FVII activation pocket and the formation of a salt bridge with an 
Asp343 side chain (Higashi et al., 1994; Petersen et al., 1999). Therefore, although 
activated, FVIIa does not express its full procoagulant functionality until bound to 
TF.(Monroe and Key, 2007). This extreme cofactor dependence of FVIIa ensures that the 
blood clotting cascade is triggered at the appropriate place and time (Persson, 2006). 
The complex FVIIa/TF catalyzes the activation of both factor IX and factor X, the latter 
initially being the more efficient substrate. FVIIa/TF/FX complex constitutes the 
extrinsic FXase, which produces the initial amount of FXa necessary to trigger the 
coagulant cascade. As the extrinsic tenase complex is rapidly shut down by TFPI, 
generation of thrombin is indirectly maintained by the FXa generation through the 
intrinsic tenase complex (where FIXa participates). (Mann et al., 2003) (Figure 5). 
 
 
Fig.5 A computational estimation of the temporal dependence of the relative FXa 
production by the extrinsic FXase (◊) and the intrinsic FXase (■) complexes. The clot 
time (CT, arrow) represents the time at which free thrombin levels are predicted to reach 
2nM. (from (Hockin et al., 2002)) 
 
In addition to the TFPI inhibition of the TF-FVIIa-FXa complex (see above), 
antithrombin III (AT III), the major plasma inhibitor of coagulation proteases, also 
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inhibits free FVIIa at a very slow rate(Rao et al., 1995), but rapidly in complex with TF 
in the presence of heparin (Rao LV, Blood 1995). This has important implications for the 
clinical use of recombinant FVIIa (rFVIIa) for management of bleeding. As a matter of 
fact, a pharmacokinetic study in hemophilic patients suggests that complex formation 
between rFVIIa and AT is the main clearance pathway for exogenously administered 
rFVIIa, accounting for 65% of a therapeutic dose (90 µg/kg) of rFVIIa (AGERSØ et al., 
2011). 
FVIIa	  in	  Hemophilia	  
 
Genetic or acquired deficiencies in Factor VIII and Factor IX (precursors of the intrinsic 
FXase) lead to the most common bleeding disorders, hemophilia A and hemophilia B, 
respectively. One in 5000 male newborns is a carrier of a defective gene leading to factor 
VIII deficiency, and 1 in 30 000 male newborns has factor IX deficiency (Stonebraker et 
al., 2012; 2010). The most effective treatment of congenital hemophilia A and B patients 
consists of regular prophylactic infusions of plasma-derived or recombinant FVIII or 
FIX, respectively. However, a major impediment for replacement therapy is the 
development of inhibitory antibodies (inhibitors) against the treatment(Walter et al., 
2013). The incidence of inhibitor formation is approximately 30% for hemophilia A and 
3% for hemophilia B. As eradication of the inhibitor therapy is not feasible in a portion of 
patients, hemostasis can only be achieved with “inhibitor bypassing agents”, such as 
recombinant activated Factor VII (rFVIIa). 
Recombinant FVIIa (rFVIIa, NovoSeven® ) was first approved in Europe in 1996 for the 
treatment of bleeding episodes in patients with congenital hemophilia and inhibitors to 
FVIII or FIX or acquired hemophilia(Abshire and Kenet, 2004).  
Due to the short half-life rFVIIa is administered repeatedly, starting with a bolus injection 
of 90–120 µg/kg, given every second hour, until hemostasis is achieved. This regimen 
was shown to be effective for both treatment of acute bleeding episodes (on-demand 
treatment) and prevention of surgery-associated bleeding The incidence of thrombotic 
events in hemophilic patients with the use of rFVIIa is extremely low. It appears to be 
lower than the thrombotic risk seen with other clotting factor concentrates with known 
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thrombogenic potential(Kenet and Martinowitz, 2008). In addition to congenital 
hemophilia with inhibitors, rFVIIa is used in patients with acquired haemophilia, 
congenital FVII deficiency or Glanzmann’s thrombasthenia. rFVIIa is also prescribed for 
off-label purposes, including reversal of anticoagulant therapy, neonatal coagulopathies; 
severe hepatic disease; high-risk surgical procedures (Ratko et al., 2004). In the past 
years the off-label use of rFVIIa for hospitalized patients has increased, despite concerns 
about efficacy and safety, including evidence suggesting an increased rate of 
thromboembolic events(Yank et al., 2011). 
 
FVIIa	  mechanism	  of	  action	  in	  hemophilia	  
 
Despite its widespread use, the mechanism of action of high dose administration of 
rFVIIa in hemophilia remains controversial and two possible models have been proposed. 
The first postulates that rFVIIa generates hemostatic amounts of Factor Xa via a TF-
rFVIIa complex on the surface of TF-expressing cells at the site of injury. As a result, the 
therapeutic rFVIIa doses are large since rFVIIa must compete with endogenous Factor 
VII (FVII) for binding to TF (Butenas et al., 2003; Veer et al., 2000). The second 
proposal centers on a TF-independent mode of action and the poor affinity of FVII for 
anionic phospholipid membranes (Kjalke et al., 2007), a necessary scaffold for 
coagulation reactions to occur. Consequently, large doses of rFVIIa are required for 
treatment in order to overcome this deficiency and generate hemostatic amounts of FXa 
in a TF-independent fashion on platelets(Hoffman et al., 2011). Mathematical modeling 
and in vitro experiments have attempted to unify these two proposals, implicating a 
predominantly TF-dependent and a minor, TF-independent component in rFVIIa's action 
(Shibeko et al., 2012). However, the functional separation of the TF and phospholipid 
binding properties in FVII and activated FVII (FVIIa) is challenging since both reside in 
the relatively short Gla domain of the molecule. As a result, the apparent controversy in 
the contribution of TF in rFVIIa’s mode of action has not been sufficiently addressed, 
especially in vivo. A better understanding of rFVIIa’s mechanism of action could suggest 
ways to improve its therapeutic and safety profile. 
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FVIIa	  molecular	  engineering	  	  
 
One of the limitations of rFVIIa therapy is the high dose required to provide effective 
hemostasis (Abshire and Kenet, 2004). Different efforts to enhance the procoagulant 
activity of rFVIIa have focused on chemical modification/formulation or the rational 
design of novel, high-specific activity variants of rFVIIa. Despite the activation, FVIIa 
has a zymogen like conformation and needs TF in order to transition in the active enzyme 
form.  
Without structural information about the latent, zymogen-like conformation of free 
FVIIa, altering the properties of rFVIIa by mutagenesis was dictated by rational design. 
Three substitutions were introduced in the serine protease domain of FVIIa 
(V158D/E296V/ M298Q-FVIIa; NN1731) based on the structure of other members of the 
trypsin family (Persson et al., 2001). The NN1731 molecule adopts a conformation 
intermediate between that of the free (zymogen-like) and the TF-bound (active) forms of 
FVIIa. Thus, it acquires its enhanced activity by partial mimicry of TF-induced activation 
even in absence of cofactor(Rand et al., 2008). NN1731 showed enhanced procoagulant 
and antifibrinolytic activities in an in vitro model of hemophilia, as well as higher 
hemostatic efficacy in a mouse model of hemophilia relative to wild-type (Bouwens et 
al., 2013; TRANHOLM et al., 2003). 
Novo Nordisk A/S started a clinical trial with the NN1731 analogue (Vatreptacog alfa) 
with the aim of providing an improved bypassing agent offering more rapid, reliable and 
sustained resolution of acute bleeds in patients with hemophilia and inhibitors (Hoffman 
et al., 2011; Regan et al., 1996). Vatreptacog alfa has successfully passed through clinical 
trials and demonstrated a superior efficacy of compared to rFVIIa at lower doses in 
hemophilia patients with inhibitors (DE PAULA et al., 2012; Sturn, 2003). However, 
data from longer use of this variant uncovered a few patients developed anti-drug 
antibodies, including one patient with a potentially neutralizing effect in one sample. 
Some of these patients also developed cross-binding antibodies to rFVIIa and therefore 
the study has been halted. Similar impediments were also encountered in a human clinical 
trial using an enhanced activity rFVIIa molecule from Bayer Pharmaceuticals. As a 
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result, new approaches have to be exploited in order to improve rFVIIa-based 
therapeutics. 
Protein	  C	  anticoagulant	  pathway	  
 
Thrombin generation is the key event during coagulation. Ultimately, thrombin 
production is directly or indirectly regulated by anticoagulant systems, such as serpin 
inhibition, TFPI and protein C (PC) anticoagulant pathway.  When thrombin binds 
thrombomodulin (TM) on the endothelial surface, its specificity switches to anticoagulant 
substrates resulting in activation of protein C and thrombin activatable fibrinolysis 
inhibitor (TAFI, a fibrinolysis inhibitor present in plasma). The procoagulant properties 
of thrombin are lost on binding to TM because TM occupies the functionally important 
exosite I in thrombin and thereby blocks interactions with other thrombin-binding 
proteins. TM is expressed ubiquitously on the vascular endothelium, predominately in the 
capillaries where the ratio between the endothelial cell surface and blood volume reaches 
its peak. The high concentration of TM in the capillary circulation ensures that thrombin 
binds to TM (Kd ≈ 0.5 nmol) and activates PC bound to the endothelial protein C 
receptor (EPCR,(Dahlback, 2005; Thiyagarajan et al., 2007)). Activated PC (aPC) 
inactivates FVa and FVIIIa by proteolysis thereby down-regulating FXa and thrombin 
production. APC also exerts a number of cytoprotective and anti-inflammatory activities 
(Balazs, 2006; Valle et al., 2012) although such molecular mechanisms remains not fully 
elucidated (Bouwens et al., 2013; Xu et al., 2000). 
The	  Endothelial	  Protein	  C	  Receptor	  
 
The endothelial protein C receptor (EPCR) is a type 1 transmembrane glycoprotein that 
shares sequence homology with the major histocompatibility complex class 1 (MHC I) 
and CD1 family of molecules (Regan et al., 1996; Taylor et al., 2001). It is primarily 
expressed on the endothelium of large blood vessels, while it is almost absent on the 
microcirculation.  
EPCR is also present on the surface of monocytes, CD56+ natural killer cells, neutrophils 
(Fukudome et al., 1998; Sturn, 2003) eosinophils and brain capillary endothelial 
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cells(Centelles et al., 2010; Thiyagarajan et al., 2007). Moreover EPCR expression can be 
detected in embryonic giant trophoblast cells, and also identifies hematopoietic stem cells 
within murine bone marrow (Balazs, 2006; van Hylckama Vlieg et al., 2007). A soluble 
form of EPCR (sEPCR) circulates in plasma, which is generated in vitro through 
proteolytic cleavage by metalloprotease activity inducible by thrombin and other inflam- 
matory mediators (LI, 2005; Xu et al., 2000), but its physiological relevance in vivo is 
not known. 
Protein C binding to EPCR increases the rate of protein C activation by the thrombin-
thrombomodulin complex on the endothelial surface of a factor of 20 in vivo (LI et al., 
2005; Taylor et al., 2001)). The influence of EPCR on protein C activation kinetics is 
primarily on the Km for the reaction. In fact, the Km of the thrombin-TM complex for 
protein C in the absence of EPCR is far below the plasma concentration of protein C. 
EPCR binding appears to concentrate protein C on the endothelial cell surface of large 
vessels, favoring its activation (Fukudome et al., 1998; Medina et al., 2007). Accordingly 
to these observations, it has been shown that blocking EPCR in mice promotes 
thrombosis development(Centelles et al., 2010; Stearns-Kurosawa et al., 1996), and 
epidemiological studies in humans indicated that the presence of anti-EPCR 
autoantibodies in plasma resulted as a risk factor for deep venous thrombosis (DVT) in 
the general population(Oganesyan et al., 2002; van Hylckama Vlieg et al., 2007).  
EPCR null mice are not viable, and EPCR expression on the feto-maternal surface is 
critical for embryo development while is not essential in the embryo (Hansson and 
Stenflo, 2005; LI, 2005). On the other hand, Tie2 (endothelial)-directed EPCR expressing 
transgenic mice did not exhibit any gross hemorrhagic or thrombotic abnormalities and 
had normal growth and viability despite of markedly lower levels of plasma protein C. 
Those mice, however, exhibit an eightfold increase in aPC generation in response to 
infusion of thrombin and were partially resistant to a lethal dose of bacterial 
lipopolysaccharide(LI et al., 2005; Reuning et al., 1993). 
In addition to controlling the coagulation by modulating protein C-mediated 
anticoagulant pathway, EPCR has been shown to play an important role in many 
pathophysiologic processes, such as inflammation responses to infection and trauma, 
hematopoiesis, and autoimmunity. Many of these effects are mediated through EPCR-
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dependent cleavage of protease-activated receptor 1 (PAR-1) and the downstream 
signaling cascade (GHOSH et al., 2006; Medina et al., 2007; Preston, 2006). 
In addition to binding protein C, EPCR binds proteinase 3, the autoantigen in Wegener’s 
granulomatosis. This complex then binds to Mac-1 on activated neutrophils where it 
apparently inhibits tight leukocyte adhesion to activated endothelium (Oganesyan et al., 
2002; Stearns-Kurosawa et al., 1996). The proteinase 3 and protein C binding sites appear 
to be distinct. 
Structural information derived from X-ray crystallography revealed a high similarity with 
CD1d, a protein involved in the immune response against glycolipid antigens. One 
molecule of phosphatydilethanolamine was found embedded in a hydrophobic pocket of 
EPCR in a groove typically involved in antigen presentation (Figure 6).  
 
Fig. 6 Left The recombinant sEPCR (rsEPCR) molecule with a portion of the 
protein C Gla domain and a lipid molecule. In EPCR (yellow ribbon), two α-helices 
and an eight-stranded β-sheet create a groove that is filled with phospholipid (the space-
filling balls in the center). Binding of Ca2+ ions (magenta spheres) to the protein C Gla 
domain (green ribbon) exposes the N-terminal ω loop, which in the absence of EPCR 
interacts with the phospholipid surfaces on the membrane. The model of the complex 
consists of residues 7–177 of rsEPCR and the first 33 residues of the protein C Gla 
domain. Right, Surface representation of the rsEPCR molecule. Electrostatic 
potentials are mapped on the surface (red negative, blue positive). The head group of the 
lipid is solvent-exposed (yellow stick model in the center), whereas the fatty acid chains 
are buried deep in the hydrophobic groove  
. 
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A crystal structure of part of the protein C Gla domain (residues 1–33) bound to soluble 
EPCR indicated that hydrophobic residues Phe-4 and Leu-8 contained within the ω-loop 
of the protein C Gla domain and Gla residues 7, 25 and 29, were directly involved in the 
interaction (Figure 6)(Oganesyan et al., 2002; Preston, 2006). Some of these residues are 
conserved in other vitamin K dependent enzyme such as FVII, FX and Prothrombin (PT), 
as indicated in Figure 7. 
 
 
Fig. 7  Amino acid sequences in the Gla domains of human vitamin K-dependent 
plasma proteins. Numbers are based on human factor VII. Amino acid residues that are 
identical in at least four of the proteins are marked in yellow. γ indicates the γ-
carboxyglutamic acid residues. Residues that form the ω-loop, the disulfide loop, and the 
hydrophobic stack region are marked. (adapted from (GHOSH et al., 2006; Hansson and 
Stenflo, 2005; López-Sagaseta et al., 2007)) 
 
FVII/a	  is	  a	  ligand	  for	  EPCR	  
 
The idea of an additional binding site for FVII/FVIIa other than TF on the cell surface 
was first proposed in 1993 by Reuning et Al(Hedner, 2008; Reuning et al., 1993). 
Binding experiments on LPS-stimulated or non-stimulated endothelial cell (HUVEC) 
revealed the presence of at least two independent binding sites for FVII/FVIIa of which 
about 10% are TF specific. This report also suggested that the FVIIa binding site on non-
stimulated HUVEC appeared to be a common binding site for vitamin K-dependent 
proteins. The FVII/a receptor was identified as the endothelial protein C receptor only 13 
years later (GHOSH et al., 2006; Pendurthi and Rao, 2010; Preston, 2006).  
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FVII Gla domain shares high homology with PC, in particular the PC residues directly 
involved in EPCR binding (Phe 4 and Leu 8) are conserved in FVII. In addition, crystal 
structures data of EPCR bound aPC and FVII indicate that the spatial disposition of the 
residues required for interaction is conserved among the two proteins (Figure 8) (López-
Sagaseta et al., 2007; Oganesyan et al., 2002). 
 
Fig 8 Protein C activation on the endothelial surface by the trombin-
thrombomodulin complex. Thrombin (FIIa) bound to thrombomodulin cleaves EPCR-
bound protein C (PC) to generate activated PC (aPC). A magnification of the crystal 
structure shows the residues of PC directly involved in the interaction with the receptor. 
On the bottom, the same residues are indicated on the protein alignment of human PC 
(hPC) and FVII Gla domains. Adapted from (Preston, 2006; Puy et al., 2010) 
 
The interaction between FVII/a and EPCR is dependent on Ca2+ and Mg2+, as observed 
for PC/APC. The affinity of both molecules for the receptor is also comparable (Kd of 40 
nM and 30 nM for FVII and PC/APC, respectively), as assessed by diverse approaches 
including surface plasmon resonance or binding on endothelial cells with fluorescently or 
radioactively labeled FVII/FVIIa (Disse et al., 2011; GHOSH et al., 2006; López-
Sagaseta et al., 2007). Despite the similar affinity, PC concentration in plasma is 6 fold 
higher compared to FVII, implicating that PC would occupy most of the receptor at 
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physiological concentration. Nevertheless under certain conditions (e.g. therapeutic 
administration of rFVIIa in hemophiliacs), plasmatic concentrations of the two proteins 
become comparable (Hedner, 2008; NAYAK et al., 2009). Hence, under these 
circumstances, FVIIa interaction with EPCR can have relevant implication on the 
hemostatic response, either modulating protease activity or down-regulating PC 
activation by competition for receptor occupancy. In order to determine the effect and 
magnitude of FVIIa-EPCR interaction on coagulation under such therapeutic settings, in 
vivo models are required.  
Up to this date, conflicting data were reported on the effect of EPCR on FVIIa function in 
vitro. It has been shown that EPCR binding was not affecting FVIIa-mediated FX 
activation on Human Umbilical Vein Endothelial Cells (HUVECs)(GHOSH et al., 2006; 
Pendurthi and Rao, 2010). In contrast, the micromolar addition of sEPCR to plasma was 
able to prolong clotting time in a PT assay and significantly reduce FXa generation on 
neoplastic cells (H727) (López-Sagaseta et al., 2007). According to Puy(Puy et al., 2010), 
this effect was caused by an EPCR dependent sequestration of FVIIa from 
phosphatidylserine-rich regions, a necessary scaffold for coagulation. More recently, 
Disse et al (Disse et al., 2011) showed that EPCR specifically inhibits activation of FX by 
soluble TF-FVIIa only in presence of Mg2+. In this model, sEPCR did not primarily target 
the Gla domain of FVIIa but rather the Gla domain of FX to attenuate FX activation. A 
possible explanation for these controversial findings on FVIIa activity may be due to 
different factors, including the cell system used, the source of TF and the relative 
abundance/localization of TF and EPCR on the surface. Most important, these studies 
lack in vivo evidences to support the magnitude of this interaction in a flow system. Such 
evidence will provide essential mechanistic data in the action of pharmacologic FVIIa 
administration in hemophilia as well as potential approaches that exploit such interaction 
for improved FVIIa therapeutics (protein or gene-based). 
There is accumulating evidence suggesting that clotting factors in the perivascular 
space, and not only circulating plasma factors, have the potential to contribute to 
hemostatic protection. The EPCR-PC/APC complexes have been shown to internalize 
into the cytoplasm of the endothelial cells. The receptor-ligand complexes accumulate in 
a recycling compartment before being targeted back to the cell surface (NAYAK et al., 
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2009). However, it may facilitate the transcytosis of PC/aPC from the apical to the basal 
side of the cell thus helping to clear it from the circulation and reach the extravascular 
space. Also EPCR-hFVII/VIIa complexes are internalized by endothelial cells and 
undergo transcytosis from the apical to the basolateral surface (NAYAK et al., 2009). In 
vivo data have shown that EPCR appears to be involved in human FVIIa (hFVIIa) uptake 
in mice (GOPALAKRISHNAN	  et	  al.,	  2010b) and in other murine models hFVIIa has been 
found in perivascular tissues where it associates with TF after bolus administration (Hoffman	  et	   al.,	   2007) . Interestingly, hFVIIa found in the perivascular space retained 
coagulant activity for extended period of time (up to 7 days) (GOPALAKRISHNAN	  et	  al.,	  2010a).  
It has been observed that prophylactic treatment of hemophilic patients with rFVIIa was 
effective in reducing bleeding episodes up to 3 moths after suspension of 
treatment(Konkle et al., 2007). The mechanism that underlies the extended protection 
observed in these patients during the follow up is still unknown, considering the short 
half life of rFVIIa in plasma (Erhardtsen, 2000). The study of EPCR-FVIIa interaction in 
vivo might also be important to understand potential mechanisms involved in rFVIIa-
induced secondary prophylaxis.  
In order to determine the effect and magnitude of FVIIa-EPCR interaction on 
coagulation under such therapeutic settings, in vivo models are required. However, such 
in vivo models must take into account any species-specific incompatibilities. This is 
certainly the case when one looks at the interaction of FVIIa-EPCR in a mouse system 
Human and murine EPCR (hEPCR and mEPCR, respectively) share high homology: 21 
out of 23 residues of hEPCR directly involved in ligand binding are conserved in mEPCR 
(LIAW et al., 2001), and the other two are conservatively substituted (Ile-51 by Leu and 
Arg-81 by Lys). Two residues in the human PC Gla domain appear to influence the PC-
EPCR interaction, namely Phe4 and Leu8 (Preston RJ, JBC 2006). Mouse PC, the natural 
ligand for mouse EPCR, in contrast to human PC, has Phe4 and Met8. However, mouse 
FVII has Leu4 and Leu8 and has been shown to be a poor ligand for mEPCR (µM 
affinity).(Margaritis et al., 2004; Puy et al., 2011) One could utilize human rFVIIa but it 
has a poor affinity for mouse TF (Petersen 2005), hence limited hemostatic effects. 
Therefore, although the mouse has been indispensable in hemostasis research, the 
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peculiarity of the mouse EPCR and FVIIa introduces additional complications in efforts 
in vivo hemostatic effect of a FVIIa-EPCR interaction under conditions of therapeutic 
FVIIa administration. 
 
  
 22 
AIM	  OF	  THE	  STUDY	  
 
 
Understanding the role of an EPCR-FVIIa interaction in vivo in hemophilia 
treatment with rFVIIa will have mechanistic and translational ramifications. This thesis 
aims to define the effects of the EPCR-FVIIa interaction in a setting of FVIIa 
administration in hemophilia, in vivo. For this, we utilize rational design and functional 
characterization of a mouse FVIIa molecule that has mouse EPCR binding capacity as a 
true gain-of-function, without altering other properties of mouse FVIIa. These unique set 
of characteristics essentially mimic those of human rFVIIa. This allowed us to utilize this 
novel mouse FVIIa molecule in in vivo hemostatic assays and discern the role of the 
FVIIa-EPCR interaction in the hemostatic function of therapeutic rFVIIa administration. 
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METHODS	  
	  
Construction	  of	  expression	  vectors	  
 
Construction of a pcDNA3.1-based (Invitrogen, Carlsbad, CA) expression plasmid vector 
for murine FVIIa wildtype (mFVIIa) has been previously described (Larson et al., 1998; 
Margaritis et al., 2004). Chimeras of mFVIIa harboring parts of the murine protein C Gla 
domain were generated by exchange cloning of gene-synthesized appropriate fragments 
(Genscript, Piscataway, NJ). All mFVIIa constructs contained the Arg-Lys-Arg-Arg-Lys-
Arg (RKRRKR [2RKR]) sequence inserted at Arg152- Ile153 of the mature protein and a 
C-terminal HPC4 epitope tag (EDQVDPRLIDGK) for purification (Margaritis et al., 
2004; Philo, 2006). Murine soluble EPCR (amino acids 1-214, msEPCR, NCBI accession 
L39017) was generated by gene synthesis (Genscript) and cloned into pcDNA3.1 vector. 
A C-terminal Factor Xa cleavage site (IEGR) followed by an HPC4 epitope tag was also 
included. Full-length murine EPCR (mEPCR) was cloned into pcDNA3.1 (pcDNA3-
mEPCR) following reverse transctiption of total RNA from a murine 
hemangioendothelioma cell line (Babul and Stellwagen, 1969; Fukudome et al., 1998), a 
kind gift from Dr. Charles Esmon (University of Oklahoma, OK). The murine tissue 
factor (mTF) cDNA (NCBI accession NM_010171) was generated by gene synthesis 
(Genscript) cloned into pcDNA3.1 with a Zeocin resistance selectable marker (pcDNA3-
mTF). The identity of all cloned fragments and resulting vectors was verified by DNA 
sequencing. 
Expression	  and	  purification	  of	  recombinant	  proteins	  
 
Murine FVIIa, mFVIIa chimeras and msEPCR were expressed in human embryonic 
kidney (HEK 293) cells, following stable DNA transfection as previously described 
(Camire et al., 2000; Margaritis et al., 2004). Purification of recombinant proteins from 
conditioned medium was performed using a C-terminal epitope tag (HPC4), as previously 
reported (Higgins and Mann, 1983; Margaritis et al., 2004). Murine FVIIa and chimeras 
were further purified on a CHT5-I hydroxyapatite column (BioRad Laboratories, 
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Hercules, CA), to separate the γ- carboxylated from the uncarboxylated material (Larson 
et al., 1998). Protein purity was assessed by SDS-PAGE using 4–12% polyacrylamide 
gels (Invitrogen). Protein concentration for mFVIIa or its chimeras were determined 
using an average molecular weight and extinction coefficient of 50,000 and 1.39, 
respectively.  
Analytical	  Ultracentrifugation	  	  
 
To calculate the protein concentration of recombinant msEPCR, analytical 
ultracentrifugation was used to determine the average molecular weight and protein 
extinction coefficient. Sedimentation velocity was performed at 45K rpm in (20 mM 
HEPES, 150 mM NaCl, pH 7.4) and 20°C using an XL-I instrument using interference 
optics in a AN60-Ti rotor and two sector cells with sapphire windows. Molecular weight 
and sedimentation coefficient were obtained by fitting g(s*) distributions using DCDT 
software, as previously described (Philo, 2006). The extinction coefficient was 
determined by differential refractometry (Babul and Stellwagen, 1969). We determined 
that the molecular weight of the recombinant msEPCR preparation was 39,700 ± 2,800 
Da, the sedimentation coefficient (s20,w) was 2.72 ± 0.05 S. Gamma-carboxyglutamic 
acid analysis on all recombinant proteins was performed as previously described (Camire 
et al., 2000). 
Generation	  of	  CHO-­‐K1	  stable	  cell	  lines	  expressing	  full-­‐length	  murine	  EPCR	  and	  
tissue	  factor	  
 
To generate a stable cell line expressing full-length mEPCR or mTF, CHO-K1 cells 
(ATCC® Catalog No. CCL-61) were transfected using Lipofectamine 2000 (Invitrogen, 
for mEPCR) and selected in 1 mg/ml G418-sulfate or 400 µg/ml zeocin growth medium 
(Invitrogen, for mTF). Resistant colonies were screened by flow cytometry using an anti-
mEPCR antibody (anti-mouse CD201-APC 0.5 µg/ml, eBioscience, San Diego, CA) or 
an anti-mTF antibody (goat anti-mTF at 4 µg/ml, Cat. AF3178, R&D Systems, 
Minneapolis, MN) followed by a Alexa-Fluor 488 labeled donkey anti-goat IgG (2 µg/ml, 
Cat. A-11055, Invitrogen). Geneticin- or zeocin-resistant CHO-K1 cells (negative 
controls for cell binding experiments) were generated by stable transfection of an empty 
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pcDNA3 vector harboring a neomycin or zeocin resistance marker (respectively) and 
selection in appropriate medium, as described above. 
Phospholipid	  Binding	  assay	  
 
Phospholipid vesicles containing phosphatidylcholine and phosphatidylserine (PC:PS, 
75:25 % [w/w]) were prepared as described previously(Higgins and Mann, 1983). 
Binding assays were performed as previously described (Dahlback, 2005; Saller et al., 
2006; Vadivel and Bajaj, 2012). Recombinant mFVIIa or mFVIIa-FMR was incubated 
for 2 h on plates coated with 50 µl of 80 µM PC:PS vesicles in TBS (50 mM Tris, 150 
mM NaCl, 5 mM CaCl2 pH 7.4)-0.2% BSA (TBS-BSA). Plates were washed 3 times 
with TBS-0.5% Tween-20, to remove non-specifically bound material. Bound protein 
was visualized colorimetrically (at 492nm) with mouse monoclonal anti-HPC4 antibody 
(1 µg/ml in TBS-BSA) and a secondary rabbit anti-mouse HRP conjugated antibody 
(1:1000 in TBS-BSA, Dako) Following subtraction of non-specific signal (phospholipids 
alone or protein alone), calculation of Kdapp calculation and non-linear regression analysis 
was performed using the GraphPad Prism v5.0b Macintosh software package. 
 
Isothermal	  titration	  calorimetry	  (ITC)	  
 
All proteins were dialyzed overnight versus 20 L of 20 mM HEPES, 150 mM NaCl, 1.6 
mM Ca2+, 0.6 mM Mg2+ and pH 7.4 (“Reaction Buffer”). Proteins were concentrated 
after dialysis by centrifugal ultrafiltration using an Amicon Ultracel 30K device 
(Millipore, Billerica, MA) and centrifuged to remove particulate material. Buffers and 
proteins were degassed before use. ITC experiments were performed at 25°C using a 
MicroCal ITC200 microcalorimeter (GE Healthcare, Piscataway, NJ). A reaction mixture 
for ITC (204 µl) of mFVIIa-WT (25 µM) or its chimeras was loaded into the sample cell. 
Titration curves were initiated by injection of 0.8 µl msEPCR (250 µM) followed by 
successive 2 µl injections of msEPCR every 180 s, under continuous stirring. Injections 
of ligand into reaction buffer were performed to determine baseline corrections. The 
integrated heats from each injection, normalized to the moles of ligand per injection, 
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were fit to a single-site binding isotherm using ORIGIN v7 (OriginLab Corp., 
Northampton, MA). The integrated peak of the first injection was excluded from the fit. 
Lack of proteolysis during the experiment was verified by SDS PAGE analysis of 
samples prior to and after ITC. The heat of dilution of msEPCR into buffer under the 
same experimental conditions (background) was subtracted from the fitted data. 
Cell-­‐surface	  binding	  assay	  
 
Determination of ligand binding to cell-surface exposed receptor (mEPCR or mTF) was 
performed as previously described(GHOSH et al., 2007)with some modifications. 
Specifically, confluent monolayers in a 24-well plate of mEPCR-expressing (CHO-K1-
mEPCR), or G418 resistant CHO-K1 cells were incubated with increasing concentration 
of ligand in Buffer “B” (10 mM HEPES, 150 mM NaCl, 4 mM KCl, 11 mM Glucose, 
1mg/ml bovine serum albumin [BSA], 1.6 mM Ca2+, 0.6 mM Mg2+) at 4 °C on ice for 1 
h. After 4 washes with ice-cold Buffer “B”, the surface-bound ligand was eluted with 
Buffer “C” (10 mM HEPES, 150 mM NaCl, 4 mM KCl, 11 mM Glucose, 1 mg/ml BSA, 
5 mM ethylenediaminetetraacetic acid [EDTA]) and subjected to polyacrylamide gel 
electrophoresis and detection by western blotting. Protein presence in the eluates was 
detected with a mouse monoclonal anti-HPC4 antibody (5µg/ml, (Margaritis et al., 2004)) 
and a secondary goat anti-mouse IgG antibody (IR-Dye CW800, 1:10000 dilution, Li-Cor 
Biosciences, Lincoln, NE). Blots were imaged at 169 µm with Odyssey imager (Li-Cor 
Biosciences). After image background subtraction, band intensities were quantified and 
corrected by nonspecific binding using the ImageJ software (Schneider et al., 2012). Only 
the heavy chain intensity of each recombinant protein was used for quantification due to 
the non-specific signal from BSA in the reaction buffer overlapping with the trace 
amounts on zymogen in each blot. Integrated densities were plotted and affinity constants 
(Kd) were calculated using a one-site specific binding curve fitting with GraphPad Prism 
v5.0b (GraphPad Software, Inc., La Jolla, CA). Conversion to nM was done using the 
integrated densities of known amounts of ligand in Buffer “C”, electrophoresed and 
blotted as described above. 
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Factor	  Xa	  generation	  assay	  
 
Mouse FX (mFX) and activated mFX (mFXa) were kind gifts from Dr R. M. Camire 
(The Children’s Hospital of Philadelphia, PA). CHO-K1 expressing mTF were seeded on 
a 96 well plate (1.3E4 cells/well, Cat. 353872, BD PrimariaTM Clear MicrotestTM Plate) 
48 h before the experiment. Confluent monolayers were washed twice with Reaction 
Buffer (20 mM HEPES, 150 mM NaCl, 0.1% (w/v) PEG 8000 pH 7.45, 1.6 mM Ca2+, 
0.6 mM Mg2+) and placed on an Eppendorf MTP Thermoblock at 37°C. One hundred pM 
of mFVIIa or mFVIIa-FMR in reaction buffer were added. The reaction was initiated 
after 3 minutes by adding murine FX (mFX, 160 nM final concentration) in a 100 µl total 
reaction volume. At selected time points (0-30 min) an aliquot of the reaction mixture 
was diluted in Quench Buffer (20 mM HEPES, 150 mM NaCl, 0.1% (w/v) PEG 8000 pH 
7.45, 50 mM EDTA). Chromogenic substrate S-2222 (DiaPharma, West Chester, OH) 
was added at a final concentration of 400 µM and activated mFX (mFXa) generation was 
monitored by measuring A405 at 22°C using a VMax plate reader (Molecular Devices, 
Menlo Park, CA). The concentration of mFXa generated over time was calculated by 
interpolation of the initial rate of hydrolysis of S-2222 by known amounts of mFXa (0-11 
nM) in Quench Buffer. 
 
Thrombin	  generation,	  coagulation	  assays	  and	  determination	  of	  mFVIIa	  antigen	  
 
Thrombin generation was determined according to methods previously described 
((Ivanciu et al., 2011), (Bunce et al., 2011)). Prothrombin time (PT) assays on plasma, 
cell culture supernatants, and purified proteins were determined as previously described 
(Margaritis et al., 2011) using human Factor VII deficient plasmas (George King Bio-
Medical Inc, Overland Park, KS) and Innovin (Siemens Healthcare, Malvern, PA). 
Quantification was performed using standard curves of increasing concentration of each 
recombinant protein. Determination of uninhibited (free) mFVIIa or mFVIIa-FMR in 
mouse plasma was performed by an ELISA, as previously described (Margaritis et al., 
2011) and/or a clotting-based assay with standard curves of increasing concentration of 
each recombinant protein. 
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Animal	  experiments	  and	  procedures	  
 
All experimental procedures were reviewed and approved by the Institutional Animal 
Care and Use Committee (IACUC) at The Children's Hospital of Philadelphia. Weight 
and age (8-12 weeks) matched male Hemophilia B (Lin et al., 1997), Hemophilia A (Bi et 
al., 1995) mice backcrossed on C57BL/6 background for at least 6 generations and 
hemostatically normal male mice (C57BL/6 background, The Jackson Laboratory, Bar 
Harbor, ME) were used in all experiments. Blood was collected via the retro-orbital 
plexus into 3.8% citrate. For EPCR blocking experiments, a rat monoclonal anti-EPCR 
antibody (RCR-252, Cat. E6280, Sigma) or isotype rat IgG (Cat. 0108- 01, Southern 
Biotech, Birmingham, AL), both in PBS, were infused via tail vein within 1 hour prior to 
the administration of mFVIIa or variant. Quantification of recovery and antigen levels in 
Figure 6 was determined by a clotting-based as well as an antigen-based (see above) 
assay, reported as an average of both. 
Murine	  carotid	  artery	  thrombosis	  and	  murine	  tail	  clip	  hemostasis	  models	  
 
Ferric chloride–induced injury was performed according to our previously published 
procedures (Ivanciu et al., 2011) using 7.5% FeCl3. In some experiments, antibody 
(RCR-252 or isotype IgG [see section above]; 50 µg in 100µl of PBS) was infused 30 
min prior to the initiation of the FeCl3 carotid artery injury model. The tail clip assay was 
performed according to our published procedures(Ivanciu et al., 2011; Margaritis et al., 
2004; 2011; 2009) with some modifications. Mice were anesthetized with isoflurane, the 
tail was pre-warmed at 37 °C and the distal portion transected at a diameter of 3 mm. The 
tail was then placed in a conical tube containing 14 ml of saline at 37 °C and blood was 
collected for 2 min. Procoagulant or PBS was then infused via the jugular vein, the 
injured tail was immediately moved to a fresh tube of saline (14 ml at 37 °C), and blood 
was collected for an additional 8 min. Quantitative assessment of blood loss was 
determined by measuring total hemoglobin by absorbance at 575 nm following red cell 
lysis and converted to total blood loss (µl) using an appropriately established standard 
curve. 
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Statistical	  analysis	  
 
Two-tailed Mann-Whitney U and Kruskal-Wallis tests were performed using the 
GraphPad Prism v5.0b Macintosh software package (GraphPad Software). Statistical 
differences were considered significant when P < 0.05. 
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RESULTS	  
 
Generation	  of	  mFVIIa	  constructs	  with	  affinity	  to	  mEPCR	  
 
Since protein C (PC) interacts with EPCR through the Gla domain (Oganesyan et al., 
2002), we generated two chimeric mFVIIa molecules with modified Gla domains using 
either part or the entire Gla domain of murine protein C (mPC) (Figure 1). Both chimeric 
molecules, as well as mFVIIa, contain a PACE/furin cleavage site enabling their 
secretion in the two-chain, activated form, as we have previously shown (Margaritis et 
al., 2004; 2009; 2011). The chimeric mFVIIa-(1-43 mPC) molecule contains the full 
mPC Gla domain and therefore should exhibit maximal affinity of the chimeric molecule 
to mEPCR. However, such modification of the Gla domain could perturb the coagulant 
activity of the resulting molecule. For this reason, we generated a minimally-mutated 
chimeric molecule mFVIIa-FMR that contains the first 11 amino acids of secreted mPC, 
resulting in just three amino acid changes relative to mFVIIa (L4F, L8M and W9R, 
Figure 1). We utilized this part of the mPC Gla domain because it defines the specificity 
of the PC-EPCR interaction (Preston, 2006). 
  
 31 
 
 
Fig. 1 Structure of the recombinant proteins used in this study. All proteins have a γ-
carboxyglutamic acid (Gla) domain, two epidermal growth factor (EGF) domains (EGF-1 
and EGF-2) and a catalytic domain. A recognition site (Arg-Lys-Arg-Arg-Lys-Arg 
[RKRRKR]) for a paired amino acid cleaving enzyme (PACE)/furin type protease is 
inserted after the Arg at position 151. The sequence of the Gla domain is shown and 
highlighted in blue for each protein. Changes in the Gla domain compared to mFVIIa 
taken from the murine PC Gla domain are highlighted in orange. Numbering refers to the 
mature form of each protein. 
 
Expression	  of	  mFVIIa	  chimeras	  
 
We generated stable clones of HEK293 cells expressing either mFVIIa, mFVIIa-FMR, 
mFVIIa-(1-43 mPC) or murine soluble EPCR (msEPCR) and purified recombinant 
proteins. For mFVIIa and its chimeras, the inclusion of a hydroxyapatite column 
purification step ensured that purified material had a full complement of Gla domain 
modifications, confirmed by γ-carboxyglutamic acid analysis (data not shown). SDS-
PAGE of purified proteins under reducing or non-reducing conditions revealed that 
mFVIIa and its chimeras were secreted and purified in the activated, two-chain form 
(Figure 2, lanes 2, 4 and 6). In order to accurately determine the msEPCR protein 
concentration, the E280 0.1% extinction coefficient of the msEPCR protein preparation 
(0.66) was determined by differential refractomery in the analytical centrifuge (Babul and 
Stellwagen, 1969). 
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Fig. 2 Coomassie brilliant blue staining of SDS PAGE gel of purified proteins. Five 
µg of mFVIIa, mFVIIa chimeras or msEPCR were electrophoresed under reducing or 
non-reducing conditions. The apparent molecular weights of the marker standard (M) are 
indicated in kDa. Lanes 1,3,5 and 7: non-reducing conditions; lanes 2,4,6,8: reducing 
conditions. Arrows point to the full-length (F) (under non-reducing conditions) and the 
heavy (H) and light (L) chains (under reducing conditions) of each protease. 
 
Generation	  of	  CHO-­‐K1	  stable	  cell	  lines	  expressing	  full-­‐length	  murine	  EPCR	  
and/or	  TF	  
 
In order to assess the ability of the mFVIIa chimeras to bind to murine EPCR as a gain-
of-function when the receptor is presented in a phospholipid membrane context, we 
generated a stable cell line expressing full-length mEPCR (CHO-K1-mEPCR) in a 
homogeneous fashion, verified by flow cytometry (Fig 3). We also generated a CHO-K1-
based mTF expressing cell line (CHO-K1-mTF) for cofactor binding experiments and 
functional assays. To control for non-specific binding, CHO-K1 cells stably transfected 
with empty expression vector were also generated. 
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Fig. 3 Scatter plots of CHO-K1 clones expressing mEPCR or mTF on the cell 
surface. CHO-K1 cells were dissociated in non-enzymatic dissociation buffer (Gibco) 
and stained for mEPCR and mTF. Receptor expression was evaluated by flow cytometry, 
quadrants were defined by negative controls (CHO-K1 naïve cells stained for both 
receptors). 
 
mFVIIa	  chimeras	  bind	  to	  mEPCR	  when	  expressed	  on	  the	  cell	  surface	  or	  in	  
solution	  
 
CHO-K1-mEPCR (or control CHO-K1) cells were incubated with increasing 
concentration of ligand (mFVIIa or its chimeras) at 4°C for 1 h in presence of 
physiological concentrations of Ca2+ and Mg2+ ions to ensure maximal binding, as has 
been previously shown for human PC and EPCR (Kurosawa, 1996). Analysis of bound 
ligand showed that mFVIIa lacked appreciable affinity to mEPCR (Figure 4, left panel) 
even at high concentration (1 µM), as expected (Puy et al., 2011; Sen et al., 2012). In 
contrast, both mFVIIa-FMR and mFVIIa-(1-43 mPC) showed specific and dose-
dependent binding to mEPCR (Figure 4, middle and right panel, respectively). 
Fluorescent densitometric analysis allowed us to estimate a Kd of interaction of 0.34 ± 
0.07 µM and 0.19 ± 0.06 µM for mFVIIa-FMR and mFVIIa-(1-43 mPC), respectively. 
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Fig. 4 Recombinant mFVIIa chimeras bind to mEPCR on CHO-K1 cells in contrast 
to mFVIIa. Increasing concentration of ligand (10-1000 nM) was incubated on CHO-K1 
or CHO-K1-mEPCR cells in the presence of 1.6 mM Ca2+ and 0.6 mM Mg2+ for 1h at 
4°C. Bound fraction was eluted and visualized by fluorescence-based western blotting 
(top part, images shown in greyscale) and band intensities were quantified and corrected 
for nonspecific binding (on CHO-K1 cells). Integrated band intensities were plotted 
(bottom part) and Kd constants were calculated. Conversion to nM was done using the 
integrated densities of known amounts of each ligand and values were normalized for cell 
numbers. Depicted curves for each protein are a representative of three experiments. 
 
To further validate the interaction between mFVIIa chimeras and mEPCR, isothermal 
titration calorimetry (ITC) was used. This solution-based assay can determine the 
magnitude of the two thermodynamic terms that define the binding affinity between two 
proteins ΔH and ΔS (Leavitt and Freire, 2001), as well as the Kd and stoichiometry of 
interaction (n). In ITC, titration of msEPCR into mFVIIa, resulted in weak heat 
measurements that did not allow for the accurate determination of thermodynamic terms 
(Figure 5, left panel). This is indicative of a weak interaction between the two proteins 
(Kd > 8 µM), confirming our results from cell binding experiments (see Figure 4). In 
contrast, mFVIIa-FMR and mFVIIa-(1-43mPC) exhibited significant heat flow as a result 
of specific interaction with msEPCR, with a stoichiometry of ~1 for both chimeras, as 
 35 
shown by the resulting isotherms (Figure 5, middle and right panels, respectively). 
Moreover, the equilibrium dissociation constants obtained from data fitting (0.48 ± 0.02 
µM for mFVIIa-FMR and 0.11 ± 0.01 µM mFVIIa-[1-43mPC], Table 1) were in good 
agreement with our findings on CHO-K1-mEPCR cells.  
 
Fig 5. Recombinant mFVIIa chimeras bind to murine soluble EPCR (msEPCR) in 
contrast to mFVIIa. Upper portion of each panel: heat flow tracings were obtained upon 
successive injections (2 µl) of msEPCR into the sample cell containing 25 µM mFVIIa or 
mFVIIa chimera in dialysate at 25°C. The first injection (0.5 µl) was eliminated from the 
analysis. The heat flow profile from an identical injection of msEPCR into dialysate was 
used as a reference and is shown offset (top of upper panel) for clarity. Bottom portion of 
each panel: corrected integrated heats (Kcal/mole of injectant) were analyzed. The line is 
drawn according to parameters listed in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 36 
 
 
Table 1. Thermodynamic constants of interaction of msEPCR with mFVIIa or its 
chimeras using isothermal titration calorimetry. 
Kd: dissociation constant; n: stoichiometry of interaction; ΔG: change in Gibbs free 
energy (G); ΔH: change in enthalpy (H); ΔS: change in entropy (S); ND: not 
determined. All parameters are listed as ± 67% confidence intervals. 
 
 
Collectively, our data confirm that binding to mEPCR, either when it is presented on the 
cell surface or in solution, can be engineered as a gain-of-function to mFVIIa by 
modification of its Gla domain. This can be achieved by a small change in the ω-loop of 
the protease (mFVIIa-FMR), thus suggesting that the mEPCR minimal binding region is 
located in the first 11 residues of mPC Gla domain. 
Partial	  substitution	  of	  the	  Gla	  domain	  of	  mFVIIa	  does	  not	  affect	  its	  in	  vitro	  
activity	  
 
The Gla domain of human FVII contributes to the interaction with tissue factor (Banner 
et al., 1996) thus affecting function within the initiation of coagulation. Therefore, prior 
to further in vivo experimentation, we tested whether Gla domain modification in the 
mFVIIa chimeras perturbs coagulant function. Using a clotting based assay, we found 
that the partial Gla domain modification in mFVIIa-FMR did not affect activity (Figure 6 
A, P > 0.05 vs. mFVIIa). In contrast, full transplant of the mPC Gla domain to mFVIIa in 
the mFVIIa-(1-43 mPC) chimeric molecule abolished activity (Figure 6A, P < 0.05 vs. 
mFVIIa or mFVIIa-FMR). Therefore, we decided to further characterize the mFVIIa-
FMR molecule only, relative to mFVIIa. 
To investigate the mFVIIa-FMR affinity for the natural FVII/FVIIa cofactor (TF), we 
used CHO-K1 cells stably expressing full-length murine TF (mTF, Figure 3, right) or 
CHO-K1 controls. We performed binding experiments with increasing ligand (mFVIIa or 
Sample 
Kd 
(µM) 
n 
ΔG 
(Kcal mol-1) 
ΔH 
(Kcal mol-1) 
ΔS 
(cal mol-1K-1) 
mFVIIa >8 ND ND ND ND 
mFVIIa-FMR 0.48 ± 0.02 0.89 -8.6 - 4.7 ± 0.03 13.3 
mFVIIa-(1-43 mPC) 0.11 ± 0.01 0.85 -9.5 -4.6 ± 0.03 16.4 
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mFVIIa-FMR) concentration added, as we described for CHO-K1-mEPCR cells. Both 
Ca2+ and Mg2+ cations were present at their physiological concentration. We found that 
mFVIIa-FMR and mFVIIa exhibited similar affinity for mTF (Figure 6B), as 
demonstrated by the estimated Kd of 14.9 ± 11.1 nM (mFVIIa-FMR) and 16.9 ± 8.9 nM 
(mFVIIa). The affinity of mFVIIa to mTF is lower than previously reported (Petersen et 
al., 2005) but could be due to the assay system employed or the source of TF (soluble of 
mTF vs full length), as observed with human FVIIa and human TF (see (Sen et al., 2010) 
for references). Our data suggest that the modifications in the Gla domain present in 
mFVIIa-FMR do not affect its interaction with mouse TF or the function of the molecule, 
compared to mFVIIa. Therefore, mFVIIa-FMR is functionally equivalent to mFVIIa but 
with the added ability to bind mEPCR. 
 
 
Fig. 6 Comparison of murine TF-dependent binding and in vitro activity of mFVIIa 
and mFVIIa chimeras. (A) Using a prothrombin time clotting assay, mFVIIa and 
mFVIIa-FMR exhibit similar activity. Asterisk indicates P < 0.05 vs. mFVIIa or mFVIIa-
FMR. Data are expressed as mean ± 1 SD. NS: not statistically significant difference. (B) 
Binding of mFVIIa (!) or mFVIIa-FMR (") on CHO-K1 cells expressing mTF. 
Increasing concentration of ligand (10-250 nM) was incubated on CHO-K1 or CHO-K1-
mTF cells and bound fraction analyzed as described in Figure 3. Both ligands exhibit 
similar mTF binding. 
 
The Gla domain is also involved in the interaction with phospholipid membranes and 
therefore modulates FVIIa activity. We tested the ability of mFVIIa and mFVIIa-FMR to 
bind phosphatidylcholine:phosphatidylserine (75/25) vesicles to simulate an activated 
phospholipid surface, as described by (Saller, 2005). As shown in Figure 8, both mFVIIa 
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molecules bound liposomes with similar affinity, mFVIIa-FMR showing a slightly 
reduced Kd compared to mFVIIa (730 ± 55 nM vs 420 ± 24 nM, respecitvely). 
 
 
Figure 7. Phospholipid binding affinity of mFVIIa and mFVIIa-FMR. Increasing 
concentration (0-4µM) of each mFVIIa or mFVIIa-FMR was incubated on a 96-well 
plate precoated with a mixture of 75:25 of phosphatidylcholine:phosphatidyl serine 
phopsholipids. Following washing of unbound material, the bound protein was detected 
by western blot. Quantification of bound material allowed for determination of calculated 
affinity of each variant for such procoagulant phospholipids.  
 
 
In order to verify that mFVIIa-FMR and mFVIIa can form functional complexes with 
mTF in the context of a cell membrane, we determined the rate of generation of activated 
murine FX (mFXa) following incubation of CHO-K1-mTF cells with either mFVIIa or 
mFVIIa-FMR. As shown in Figure 8, both mFVIIa and mFVIIa-FMR exhibited similar 
rates of mFXa generation (2.20 ± 0.07 nM/min for mFVIIa and 2.00 ± 0.03 nM/min for 
mFVIIa-FMR). 
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Fig. 8 Generation of mFXa over time on CHO-K1 cells expressing mTF following 
incubation of mFVIIa (!) or mFVIIa-FMR ("). Both ligands exhibit similar rates of 
mFXa generation. 
 
In order to assess if mEPCR binding could influence mFXa generation, we co-transfected 
and subcloned  clone 14  of CHO-K1-mTF (previously used for mFXa generation 
assays), generating a CHO-K1-mTF/mEPCR expressing cell line. mTF expression 
between CHO-K1-mTF and CHO-K1-mTF/mEPCR was comparable, as confirmed by 
flow cytometry (Figure 9) analysis and mFVIIa titration assays (Figure 10). 
 
 
Fig. 9 Scatter plots and histogram of CHO-K1 clones expressing mEPCR and mTF 
on the cell surface. Left, CHO-K1 cells were dissociated in non-enzymatic dissociation 
buffer (Gibco) and stained for mEPCR and mTF. Receptor expression was evaluated by 
flow cytometry, quadrants were defined by negative controls (CHO-K1 naïve cells 
stained for both receptors). Right, histogram of CHO-K1 naïve (blue line), CHO-K1-mTF 
(red line) and CHO-K1-mTF/mEPCR (light blue line), stained for mTF. 
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Fig. 10 Functional TF determination on CHO-K1 expressing mTF or mTF and 
mEPCR mFX activation was measured at 10 min in HBS PEG 0.1% pH 7.45, 5 mM 
Ca2+, 37 C° in presence of increasing concentration of mFVIIa or FMR (0.005 – 5 nM), 
160 nM mX and 400 µM S-2222. 
 
In the presence of mTF and mEPCR, mFXa generation rates were 1.71 ± 0.10 nM/min 
for mFVIIa and 1.87 ± 0.08 nM/min for mFVIIa-FMR (Table 2). There is a trend for a 
slightly higher rate of mFXa generation vs. mTF alone (see Table 2). However, under the 
same experimental conditions, mFX activation on CHO-K1-mEPCR cells (no mTF) was 
undetectable (data not shown), collectively suggestive of small (if at all) synergistic 
mTF-mEPCR synergistic effect on mFX activation in vitro. Unfortunately, further 
analysis on such effect is difficult given that the local concentration of the receptor on the 
cell surface in relation to mTF might be suboptimal (we did not quantify receptor 
density).  
Sample nM mXa / min 
 mTF mTF mEPCR 
mFVIIa 2.20 ± 0.07 1.71 ± 0.10 
mFVIIa-FMR 2.00 ± 0.03 1.87 ± 0.08 
 
Table 2 Comparison of activation rates of mFX by mFVIIa or mFVIIa-FMR on 
CHO-K1 expressing mTF alone or mTF and mEPCR on the cell surface. Rates are listed 
as ± 67% confidence intervals. 
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Lastly, in order to characterize the overall potential of the mFVIIa-FMR relative to 
mFVIIa on thrombin production in murine plasma, we utilized a thrombin generation 
assay. To simulate hemophilia conditions, we supplemented murine hemophilia B plasma 
with 25 nM mFVIIa or mFVIIa-FMR since this is sufficient to induce hemostasis in 
hemophilic patients (Hedner, 2008). The reaction was initiated using tissue 
factor/phospholipids (Castoldi and Rosing, 2011). As previously described (Ivanciu et al., 
2011), naïve murine hemophilia B plasma resulted in undetectable murine thrombin 
generation (Figure 5D). In contrast, addition of either mFVIIa or mFVIIa-FMR resulted 
in murine thrombin generation, with mFVIIa-FMR exhibiting a modest but statistically 
significant (P < 0.05) reduction in peak of thrombin, compared to mFVIIa (Figure 11). 
This reduction was observed even when lower amounts of mFVIIa or mFVIIa-FMR 
added in the reaction (12.5 and 6.25 nM, data not shown). Despite this, mFVIIa-FMR 
exhibited similar endogenous thrombin potential (ETP, a measure of the total murine 
thrombin generated during the assay) relative to mFVIIa at all doses tested (Figure 11, 
inset graph, P > 0.05 for mFVIIa vs. mFVIIa-FMR at each dose shown). 
 
 
Fig. 11 Murine thrombin generation assay following the addition of 25 nM mFVIIa 
(!) or mFVIIa-FMR (") or buffer (!) in mouse hemophilia B plasma. Asterisk 
indicates P < 0.05 vs. mFVIIa of the entire fitted data. The inset graph shows the 
endogenous thrombin potential (ETP) following addition of different concentration of 
mFVIIa (black bar) or mFVIIa-FMR (white bar). 
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The	  mFVIIa-­‐FMR	  molecule	  binds	  mEPCR	  in	  vivo	  
 
In order to address if mFVIIa-FMR can bind mEPCR in vivo, we monitored protease 
levels in plasma over time, after intravenous bolus administration in C57BL/6 adult male 
mice. The standard hemostatic dose of rhFVIIa in hemophilic patients is 90-120 µg/kg 
(Kenet and Martinowitz, 2008). However, given the short half-life of rhFVIIa (2.5-3 
hours (Villar et al., 2004)), to ensure sufficient protein detection, mice received a dose of 
500 µg/kg of mFVIIa or mFVIIa-FMR via a single tail vein injection and blood plasma 
levels of administered protease (recovery, as percentage of injectant) were determined at 
different timepoints. As shown in Figure 12A, remarkably, within 5 min after 
administration, mFVIIa-FMR rapidly disappeared from the plasma, in contrast to mFVIIa 
(30.4 ± 6.8 % vs. 53.2 ± 19.3 % recovery, respectively, P < 0.01). This lower recovery of 
mFVIIa- FMR vs. mFVIIa was also evident at 30 and 120 min post administration (P < 
0.05 for each timepoint). 
Given the mEPCR binding capacity of mFVIIa-FMR, the lower recovery of mFVIIa- 
FMR suggests a potential mEPCR-dependent sequestration from circulation. To test this, 
we infused the RCR-252 mEPCR-blocking antibody(Deane et al., 2009)or isotype control 
IgG one hour prior to tail vein administration of 500 µg/kg mFVIIa or mFVIIa-FMR, in 
C57BL/6 mice. We assessed plasmatic levels of the administered proteins at 5 min post 
injection to maximize protein detection and differences in protein recovery. Infusion of 
RCR-252 (or control antibody) followed by PBS did not increase endogenous mFVIIa 
levels that were below the limit of quantification (Figure 12B). Since mFVIIa shows 
negligible affinity to mEPCR, administration of either mEPCR blocking or isotype 
control IgG prior to mFVIIa infusion had no effect on plasmatic levels (P > 0.05). Mice 
that received mFVIIa-FMR after isotype control IgG showed reduced plasmatic levels 
compared to mFVIIa (P < 0.05), as expected (compare to Figure 12A, 5 min). In contrast, 
blocking mEPCR prior to administration of mFVIIa-FMR resulted in increased plasmatic 
levels, similar to those observed for mFVIIa (P > 0.05, Figure 12B). Collectively, these 
data suggest that the modified Gla domain in mFVIIa-FMR allows it to bind specifically 
to mEPCR in vivo. As a result, changes observed in the mFVIIa-FMR recovery vs. 
mFVIIa are dependent on specific binding to mEPCR. 
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Fig. 12 The chimeric mFVIIa-FMR molecule can bind mEPCR in vivo. (A) C57BL/6 
mice (n=5 per group per timepoint) were infused via the tail vein with 500 µg/kg of 
mFVIIa (!) or mFVIIa-FMR (") and blood was collected at various time points 
thereafter. Plasma protein concentration was measured by antigen and activity assays and 
shown as recovery (% of the initial amount of injectant, mean ± SD). Recovery of 
mFVIIa-FMR is reduced compared to mFVIIa. Asterisk indicates P < 0.05 vs. mFVIIa. 
(B) Cohorts of C57BL/6 mice were initially infused via the tail vein with mEPCR 
blocking antibody (RCR-252) or isotype control IgG. The type of antibody administered 
in each cohort is indicated by the “+” or “-” symbol. One hour later, 500 µg/kg of 
mFVIIa, mFVIIa-FMR or buffer was infused and antigen levels at 5 min post injection 
were determined. Asterisk indicates P < 0.05 for each indicated comparison. Data are 
expressed as mean ± 1 SD. 
 
EPCR	  binding	  enhances	  FVIIa	  hemostatic	  activity	  in	  vivo	  
 
Using mFVIIa-FMR as a model of the properties of rhFVIIa (TF and EPCR binding) we 
investigated whether binding to EPCR can influence the hemostatic action of rhFVIIa in 
vivo. We chose hemophilia mice that underwent a 7.5% FeCl3 injury on their carotid 
artery. The mice were subsequently infused via the jugular vein with mFVIIa, mFVIIa-
FMR or control (PBS) and time to vessel occlusion as a result of thrombus formation was 
determined. We chose this model since EPCR expression is higher in large vessels in 
comparison to the microcirculation (Laszik et al., 1997). Moreover, we have previously 
utilized this model and procoagulant dosing to demonstrate hemostatic efficacy of 
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modified procoagulants based on activated FX (Ivanciu et al., 2011). Under the 
experimental conditions, hemostatically normal mice (WT) formed occlusive thrombi in 
14.5 ± 0.8 min (Figure 13A). As expected (Ivanciu et al., 2011), hemophilia B (HB) mice 
did not show vessel occlusion over the time of observation (data not shown). In contrast, 
administration of mFVIIa or mFVIIa-FMR resulted in stable vessel occlusion. A dose of 
3 mg/kg mFVIIa normalized the hemostatic response (as listed in table 3). Administration 
of mFVIIa-FMR at this dose resulted in stable vessel occlusion at 4.9 ± 0.6 min, 
significantly faster (~3 fold) than WT or HB mice infused with similar dose of mFVIIa 
(P < 0.05). In an effort to increase the hemostatic response of mFVIIa, we administered a 
higher dose (5 mg/kg) that resulted in vessel occlusion at 4.3 ± 1.0 min, similar to the 3 
mg/kg dose of mFVIIa-FMR (P > 0.05). The enhanced hemostatic effects of mFVIIa-
FMR were also observed using a 5 mg/kg dose, that resulted in even faster vessel 
occlusion (2.6 ± 0.6 min) compared to the 3 mg/kg dose (4.9 ± 0.6 min, P < 0.05). Lastly, 
in an attempt to determine the mFVIIa-FMR dose sufficient to normalize the hemostatic 
response, we administered a 1 mg/kg dose. However, mice responded partially since only 
1/3 mice exhibited vessel occlusion at 6 minutes post protein administration (Table 3). 
To demonstrate that the enhanced hemostatic effects of mFVIIa-FMR are due to specific 
binding to mEPCR, we administered either an EPCR-blocking antibody (RCR-252) or 
isotype control in hemophilia B mice. Thirty minutes after antibody infusion, we 
performed a 7.5% FeCl3 carotid artery injury followed by infusion of 3 mg/kg of 
mFVIIa-FMR. As expected, the enhanced hemostatic properties of mFVIIa-FMR were 
unaffected by the control IgG infusion (vessel occlusion at 4.7 ± 1.1 min, Figure 13B). In 
contrast, blocking mEPCR resulted in a statistically significant increase in vessel 
occlusion time (11.6 ± 4.2 min, Figure 7B, P < 0.05 vs. IgG), similar to what was 
observed with mFVIIa (3 mg/kg, Figure 13A).  
Lastly, in order to confirm that the differences in the hemostatic effects of mFVIIa-FMR 
vs. mFVIIa are not disease specific, we administered 3 mg/kg of mFVIIa or mFVIIa-
FMR in hemophilia A (HA) mice. Similar to HB mice, infusion of mFVIIa-FMR resulted 
in faster vessel occlusion than mFVIIa (2.8 ± 0.6 min vs. 13.8 ± 1.1 min, respectively, P 
< 0.05, Figure 13C).  
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Fig. 13 Infused mFVIIa-FMR shows enhanced hemostatic potential in hemophilic 
mice compared to mFVIIa. (A) Hemophilia B mice (n=3-5 per group) were subjected to 
a 7.5% FeCl3 injury and blood flow was monitored for 10 minutes. Subsequently, 
procoagulant (mFVIIa or mFVIIa-FMR) was administered at the indicated dose via the 
jugular vein and time to vessel occlusion was determined. Wildtype (WT) mice (n=4) are 
shown for reference (white bar). Data are shown as mean ± 1 SD. Asterisk indicates P < 
0.05 vs. mFVIIa for each procoagulant dose; hash tag indicates P < 0.05 vs. WT; NS 
indicates non-significant difference. (B) Hemophilia B mice (n=3-4 per group) were 
injected with 50 µg of EPCR-blocking antibody (RCR-252) or control isotype IgG. 
Thirty minutes later, they were subjected to a 7.5% FeCl3 injury and blood flow was 
monitored for 10 minutes. Subsequently, mFVIIa-FMR was administered at 3 mg/kg via 
the jugular vein and time to vessel occlusion was determined. Data are shown as mean ± 
1 SD. Asterisk indicates P < 0.05 vs. IgG. (C) Hemophilia A mice (n=4-5 per group) 
were subjected to the same experimental setup as in (A). Data are shown as mean ± 1 SD. 
Asterisk indicates P < 0.05 vs. mFVIIa. 
 
Table 3 Time to carotid artery occlusion following FeCl3-induced injury WT, 
C57BL/6 mice; HB or HA, hemophilia B (or A) mice; Occlusion time measurements are 
presented as mean ± s.e.m. and are derived from both transient and complete events. ‘–‘ 
indicates that no clot was observed during the observation period (30 min). 
Mice Sample Dose (mg/kg) n 
No 
occlusion Complete 
Time to 
occlusion (min) 
WT PBS - 5 - 5 14.5 ± 0.3 
HB mFVIIa 5 3 - 3 4.3 ± 0.6 
HB  3 4 1 4 12.9 ± 1.4 
HB mFVIIa-FMR 5 3 - 3 2.6 ± 0.4 
HB  3 5 - 5 4.9 ± 0.3 
HB  1 3 2 1 6 
HA mFVIIa 3 4 - 4 13.8 ± 0.8 
HA mFVIIa-FMR 3 5 - 5 2.8 ± 0.3 
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To further show that the increased hemostatic effects of mFVIIa-FMR are not injury 
model-specific, we utilized a different challenge. Specifically, hemophilia B mice had 
their tail transected and blood volume loss was measured for 2 minutes. Then, 3 mg/kg of 
procoagulant (mFVIIa or mFVIIa-FMR) or PBS (control) was infused via the jugular 
vein and subsequent blood volume loss was measured for an additional 8 minutes (Figure 
14). The dose of procoagulant was chosen on mFVIIa normalizing the vessel occlusion 
time in the FeCl3 carotid artery model (mFVIIa vs. WT, Figure 14). In this experimental 
setting (Figure 14), blood loss in WT mice was significantly less compared to HB mice 
either prior to infusion (“PRE”, 40 ± 23 µl vs. 173 ± 90 µl, respectively; P < 0.05) or after 
infusion of PBS (“AFTER”, 13 ± 18 µl vs. 346 ± 78 µl, respectively; P < 0.05). Infusion 
of procoagulant in HB mice led to a significant decrease in blood loss, compared to PBS 
(P < 0.05 for either mFVIIa or mFVIIa-FMR treated HB mice; 175 ± 72 µl and 48 ± 34 
µl, respectively). Although both procoagulants normalized blood loss (P > 0.05 vs. WT), 
mFVIIa-FMR infusion was ~3 fold more effective in reducing blood loss compared to 
mFVIIa (P < 0.05), indicating its increased hemostatic capacity compared to the parent 
molecule (mFVIIa). 
In conclusion, based on the properties of mFVIIa-FMR, our data suggest for the first time 
that its specific binding to EPCR enhances its procoagulant effect in vivo. 
 
 
Fig. 14 Tail Clip and protein infusion in hemophilic mice. Hemophilia B mice (!, n= 
4-5 mice per group) or wildtype (☐, n= 5 mice) were subjected to a tail transection and 
blood loss (in µl) was measured for a period of 2 minutes (“PRE” period). Immediately 
after, 3 mg/kg of mFVIIa or mFVIIa-FMR were infused and blood loss (in µl) was 
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measured for an additional 8 minutes (“AFTER” period). Wildtype mice infused with 
PBS are shown as a reference. Data are shown as mean ± 1 SD. Asterisk indicates P < 
0.05 vs. WT mice; hash tag indicates P < 0.05 vs. mFVIIa. 
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DISCUSSION	  
 
Although the hemostatic effects of rFVIIa administration in hemophilia are undisputed, 
its mechanism of action remains unclear. Moreover, the functional significance of the 
FVIIa-EPCR interaction as it relates to pharmacologic rFVIIa administration has also 
remained unestablished. In order to perform in vivo studies investigating the significance 
of this interaction in human physiology and pathophysiology, it is fundamental to 
establish and characterize a proper murine model, taking into account the poor affinity of 
murine FVIIa for mEPCR. This apparent species discrepancy makes the mouse a minimal 
background system with respect to the interaction of EPCR with endogenous or 
exogenously administered mFVIIa. 
Here, we have characterized a novel chimeric mFVIIa molecule (mFVIIa-FMR) that, in 
contrast to mFVIIa, merges normal TF-dependent binding/activity and gains EPCR 
binding. This result exemplifies the plasticity of mFVIIa and identifies for the first time 
the region in the mPC Gla domain responsible for specific binding to mEPCR. In vivo, 
mFVIIa-FMR was rapidly sequestered from the circulation by an EPCR-mediated 
mechanism that was completely abolished by antibody blocking of the receptor. Using 
two established injury models in hemophilic mice, we show that mFVIIa-FMR infusion 
exhibited a superior hemostatic capacity compared to mFVIIa that was dependent to its 
binding to endogenous EPCR. Based on our mouse model and the properties of mFVIIa-
FMR that mimic those of rFVIIa, our results demonstrate for the first time in vivo that 
EPCR contributes to the correction of hemostasis by high dose rFVIIa in hemophilia. 
Remarkably, the magnitude of this enhanced hemostatic capacity suggests that EPCR is 
unlikely a minor effector of function of this chimeric molecule. 
Our data indicate that EPCR is a component of rFVIIa’s hemostatic function, 
however how a receptor localized on the endothelium can participate in FVIIa-
procoagulant reactions is not immediately profound. Traditionally the endothelium has 
been considered as a substantial anticoagulant surface. In fact, the endothelial cells are 
rich in glycosaminoglycans (a physiologic heparin-like cofactor of antithrombin) and also 
synthesize TFPI and most of the fibrinolityc activator (Levi et al., 2002). Moreover, the 
endothelium expresses thrombomodulin and EPCR in order to sustain effective aPC 
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generation on its surface and provide downregulation of thrombin production. On the 
other hand, activated platelets were generally regarded as the only source of procoagulant 
membranes, strictly localizing coagulant reactions by exposing anionic phospholipids on 
their surface (Heemskerk and Bevers, 2002). With the advancing of intravital microscopy 
techniques, the role of platelets in coagulation has been reshaped (Ivanciu et al., 2012) 
and vascular endothelium appear to have the capacity of further supporting clotting 
reactions and prothrombinase assembly even in absence of platelet activation 
(Vandendries et al., 2006). It has been shown that laser-activated endothelium can 
provide TF and support fibrin formation, including platelet accumulation and activation 
at the site of injury(Atkinson et al., 2010; Dahlback, 2005; Kroh et al., 2011). This 
indicates that upon stimulus, these cells can be converted from a quiescent noncoagulant 
state to an activated procoagulant state that supports thrombin-generating reactions. 
In this perspective, a plausible explanation for the enhanced activity of the 
chimera observed in vivo is that the EPCR binding capacity of mFVIIa-FMR is an 
additional endothelial recruiter of the molecule in proximity to and/or the site of the 
injury where it participates in procoagulant reactions. The “preventive” localization of 
FVII/FVIIa on the vessel wall might accelerate thrombus formation dynamics by 
tethering the protease on the surface where TF might be exposed upon injury or cellular 
signaling events. 
Moreover, since TF-FVIIa-EPCR can form a complex with FX/FXa,(Disse et al., 
2011) EPCR tethering of mFVIIa-FMR on the endothelium may provide an extended 
locale of procoagulant reactions leading to the observed enhanced procoagulant effects of 
mFVIIa-FMR vs. mFVIIa. However, these reactions may not be confined exclusively on 
the endothelial surface; for example, monocytes express functional EPCR and, upon 
stimulation, TF (Osterud, 2012).  
EPCR occupancy by mFVIIa-FMR may also downregulate activated mPC 
generation, and hence anticoagulation, resulting in the apparent enhancement of 
hemostatic function of mFVIIa-FMR. Such a hypothesis relies on effective competition 
of mPC-mEPCR binding by mFVIIa-FMR and is supported by two observations: (i) 
endogenous EPCR in mice appears to be a limiting factor for activated PC (aPC) 
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generation (LI et al., 2005); (ii) the dose of mFVIIa-FMR administered (3 mg/kg) would 
likely reach plasmatic levels well beyond those of mPC 
We have to point out that an EPCR-dependent additive FXa generation and aPC 
competition are non-exclusive hypotheses and can occur concurrently, as two converging 
components that contribute to the enhanced procoagulant response that we observed in 
different injury models.  
Our in vivo injury data suggest that infusion of mFVIIa-FMR changes the kinetics 
of thrombus formation (vs. mFVIIa), but is unclear if mFVIIa-FMR modifies the 
magnitude and/or localization of procoagulant reactions. Ultimately, experiments that 
look at real-time thrombus formation that are currently underway will add the extent and 
topographical information of these reactions. These experiments will involve 
visualization and quantification of fibrin deposition in vivo with intravital fluorescence 
microscopy techniques during laser-induced or FeCl3 induced thrombus formation. 
Preliminary experiments in mice showed that EPCR is highly expressed on the 
mesenteric artery while it was almost absent in cremaster arterioles (P. Margaritis, 
personal communication), as previously observed in humans and baboons (Laszik et al., 
1997). The comparison of fibrin formation and platelet accumulation after mFVIIa or 
mFVIIa-FMR administration in these vascular systems in hemophilic mice will help us to 
further dissect the role of EPCR in clot formation following FVIIa administration. Lastly, 
using an active site fluorescent labeling approach, we want to directly visualize FVIIa in 
the developing thrombus and determine how EPCR binding affects its localization in 
respect to platelets and other clotting factors. 
A limitation of our studies is that we did not directly compare the mEPCR 
affinities of our chimeric mFVIIa molecules to that of mPC. The affinity of mPC for 
mEPCR is unknown and several attempts to purify recombinant mPC according to 
published procedures were unsuccessful (data not shown). Recombinant material had a 
large proportion of aggregates and autolysis products that could be separated by size 
exclusion chromatography but with significant protein loss. This prevented further 
downstream purification to recover fully γ-carboxylated mPC (a necessary step for Gla 
domain dependent interactions), although the partially purified material was able to bind 
mEPCR on the cell surface. However, given that the Gla domain determines EPCR 
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binding, we speculate that the mEPCR affinity of mFVIIa-(1-43 mPC) that harbors the 
full Gla domain of mPC, should be representative of mPC (i.e. 100-200 nM). 
Unfortunately, the interaction of mFVIIa-(1-43 mPC) for the receptor was not compatible 
with a normal TF-dependent activity, hence could not be used in vivo. On the contrary, 
mFVIIa-FMR that retained normal TF binding/activity bound mEPCR substantially 
tighter than mFVIIa. Using this minimally modified molecule, we showed EPCR 
contribution on FVIIa even at binding affinities that are lower than for the endogenous 
mouse PC. Since human rFVIIa and human PC bind to human EPCR with equal affinity, 
we speculate that in humans, rFVIIa binding to EPCR might have even more relevant 
impact on its hemostatic function in hemophilia treatment. 
Previously, enhancing the function of rFVIIa has focused on amino acid 
modification relating to phospholipid membrane binding or catalytic function. Chemical 
modifications in order to increase the half-life of rFVIIa have also been explored (such as 
glycoPEGylation or formulation with PEGylated liposomes) as well as fusion to albumin 
or monomeric Fc (Peyvandi et al., 2013). Based on our data, limited mutagenesis within 
the Gla domain of human FVIIa could reveal a novel class of rFVIIa molecules with 
enhanced binding to EPCR and increased hemostatic function.  
 Recombinant human FVIIa has also been used in prophylaxis. In a study of 
rFVIIa secondary prophylaxis in hemophilic patients with inhibitors, patients receiving 
daily rFVIIa infusions for 3 months, followed by a 3-month post-prophylaxis period, 
showed clinical benefits even in the post-prophylaxis period (Konkle et al., 2007). 
Previous mouse studies suggested that rFVIIa is transported via an EPCR-dependent 
mechanism to the extravascular space, where it can persist for extended period of time in 
complex with TF,(CLARK et al., 2012) (Hoffman et al., 2007) potentially preventing 
minor bleeds before their escalation to major bleeds. Such mechanism may explain the 
prolonged clinical benefits of rFVIIa prophylaxis. In this context, enhancement of EPCR 
binding of rFVIIa could also benefit prophylaxis-based therapies. This includes gene-
based FVIIa approaches in hemophilic animal models (as previously shown in mice and 
dogs (Aljamali et al., 2008; Mann et al., 2003; Margaritis et al., 2004; 2009; 2011)) 
directing continuous expression of FVIIa to simulate a prophylaxis setting. Preliminary 
experiments using viral-mediated gene transfer of mFVIIa-FMR suggest that it can be 
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expressed long term (several weeks) in hemophilic mice (P. Margaritis, personal 
communication). Future experiments will test the involvement of EPCR in long-term 
biodistribution and hemostatic function of FVIIa by comparing mFVIIa-FMR and 
mFVIIa in this gene transfer model. Histological analyses and hemostatic challenges in 
hemophilic mice expressing such molecules will define: (1) how EPCR binding may 
affect the long-term biodistribution of mFVIIa-FMR; (2) whether such biodistribution 
changes compared to mFVIIa affect its hemostatic function. If persistence of rFVIIa 
extravascularly indeed effects long-term clinical benefits, then understanding it will help 
us improve such benefits in rationally-designed FVIIa therapeutics. 
In conclusion, using a minimal modification of the Gla domain of mFVIIa, we 
have generated and characterized a novel mFVIIa molecule (mFVIIa-FMR) with the 
capacity to interact with mEPCR in vitro and in vivo, as a true gain of function. Using the 
mouse as a relevant platform, we are first to demonstrate that EPCR is a previously 
unconsidered component of the mechanism of action of rFVIIa in hemophilia. This 
effector function of EPCR immediately suggests pathways to design novel protein or 
gene-based FVIIa therapeutics with increased efficacy and higher safety profiles. Of 
course, any potential adverse effects (immunologic or thrombotic) of such novel therapies 
will need to be properly evaluated. 
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CONCLUDING	  REMARKS	  
 
 
We modified the Gla domain of mFVIIa with 3 amino acid changes in order to create a 
gain in function in its ability to bind mEPCR without altering affinity for TF or the 
resulting function of the TF-bound protease. The resulting molecule (mFVIIa-FMR) 
suitably modeled the TF-dependent and EPCR binding properties of rFVIIa. This allowed 
us to use it in hemophilic mice to evaluate the hemostatic effects of the EPCR-rhFVIIa 
interaction for on-demand rFVIIa administration. 
In a mouse hemophilia system, the binding of administered FVIIa to endogenous EPCR 
enhanced its hemostatic properties. These results identified EPCR as an effector of 
human FVIIa infusion in hemophilia that can be exploited in novel protein or gene-based 
FVIIa therapeutics 
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